An early assessment reveals that a newly approved drug to treat migraines does not seem effective among patients who suffer from high-frequency migraines. The findings will be presented this week during the 61st annual scientific meeting of the American Headache Society in Philadelphia. Clinicians at OHSU in Portland, Oregon, conducted a retrospective chart review of